Corient Private Wealth LLC Purchases 7,190 Shares of Haleon plc (NYSE:HLN)

Corient Private Wealth LLC raised its position in shares of Haleon plc (NYSE:HLN) by 6.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,542 shares of the company’s stock after acquiring an additional 7,190 shares during the period. Corient Private Wealth LLC’s holdings in Haleon were worth $1,169,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sierra Ocean LLC bought a new stake in Haleon during the 4th quarter valued at approximately $26,000. Versant Capital Management Inc lifted its holdings in shares of Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Haleon in the fourth quarter valued at approximately $35,000. Toronto Dominion Bank boosted its position in shares of Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after acquiring an additional 3,470 shares during the period. Finally, Spire Wealth Management acquired a new stake in shares of Haleon in the fourth quarter worth $39,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Performance

NYSE:HLN opened at $10.05 on Thursday. The firm has a market capitalization of $45.47 billion, a PE ratio of 29.54, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.99 and a 12-month high of $10.80. The firm has a 50-day moving average price of $9.90 and a 200 day moving average price of $9.88.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Research analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HLN. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. HSBC reiterated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Hsbc Global Res downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon has an average rating of “Hold” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.